With the recent spike in implied volatility, an iron condor on Amgen can use short strikes with a wide profit range.

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

Despite the very positive setup facing Amgen as a result of its ongoing and future investments in developing new ...

Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded ...

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Amgen (NasdaqGS:AMGN) with a Peer Perform ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...